| Autor: |
Burd SG; Federal Center of Brain Research and Neurotechnologies, Moscow, Russia.; Pirogov Russian National Research Medical University, Moscow, Russia., Lebedeva AV; Pirogov Russian National Research Medical University, Moscow, Russia., Avakyan GG; Federal Center of Brain Research and Neurotechnologies, Moscow, Russia.; Pirogov Russian National Research Medical University, Moscow, Russia., Rubleva YV; Federal Center of Brain Research and Neurotechnologies, Moscow, Russia., Pantina NV; Federal Center of Brain Research and Neurotechnologies, Moscow, Russia., Yurchenko AV; Federal Center of Brain Research and Neurotechnologies, Moscow, Russia., Kovaleva II; Federal Center of Brain Research and Neurotechnologies, Moscow, Russia. |
| Abstrakt: |
Based on the available literature data, the article discusses the prevalence of various forms of damage of the peripheral nervous system in COVID-19 and in the post-COVID period. Information about the clinical features and the course of individual cranial neuropathies, chronic dysimmune neuropathies, Guillain-Barré syndrome, drug-induced neuropathies, fine fiber neuropathy, myasthenia gravis and polyneuropathy of critical conditions was systemized in the context of coronavirus infection. SARS-CoV-2 can trigger various stages of pathogenesis, including neuroimmune ones, which cause long-term consequences of COVID-19, including those associated with the damage of the peripheral nervous system. Awareness of COVID-19-associated pathological conditions will allow assessment of the possible risks of damage of the peripheral nervous system, recognize them at early stages and develop more effective approaches for treatment. |
